Savara is an orphan lung disease company.
Clinical Studies
Savara’s primary focus is IMPALA 2, a second Phase 3 clinical study of Molgradex for the treatment of autoimmune pulmonary alveolar proteinosis (aPAP). The company is also conducting another pivotal Phase 3 study, called AVAIL, that is evaluating AeroVanc for the treatment of MRSA in people living with cystic fibrosis.
Read more
Indications
We focus on rare respiratory diseases in order to give patients with unmet medical needs better treatment options.
Read more
Visit our PAP portal where patients and doctors can learn more about this disease
Read more

Savara Nasdaq Opening Bell Ceremony - July 23, 2018
×